Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Syngeneic Mouse Models for Pancreatic Cancer

Syngeneic Mouse Models for Pancreatic Cancer

The syngeneic mouse model effectively studies how pancreatic cancer therapies work in the presence of a functional immune system. Alfa Cytology is a leading preclinical research service provider. We have extensive experience constructing syngeneic models for pancreatic cancer (PC).

Overview of Syngeneic Models

The difference between the syngeneic mouse model, also known as the allogeneic mouse tumor system, and the humanized mouse model is the source of the cancer being monitored. In the humanized mouse model, the cancer cells were taken directly from humans, while in the syngeneic mouse model, the cancer cells came from mice or genetically similar rodents. Genetically identical mouse models are generated through a transplant or grafting procedure, in which one mouse's cells, tissues, or organs are transplanted into another mouse.

The syngeneic mouse model was established by transplanting mouse tumor cell lines into immune-functioning animals for a short period. Fig. 1 To establish a syngeneic mouse model for evaluating immunotherapy. (Chulpanova, D.S., et al., 2020)

Syngeneic transplantation is less prone to rejection and less dependent on immunosuppressive drugs. Syngeneic mouse models are used in cancer research to determine the overall efficacy of novel therapies. Tumor growth is monitored in the context of different therapies, thus providing clues to how various therapies affect tumor growth.

Our Services

Alfa Cytology offers a variety of syngeneic mouse models, including those that respond to immunotherapy. Because genetically identical mice retain intact immune systems, they are particularly suitable for immunotherapy research. Examples of uses include cancer therapies targeting immune checkpoints or immunostimulatory molecules.

Syngeneic Mouse Models for Immunotherapy

Alfa Cytology provides immunoassays and genetically evaluated syngeneic mouse models, such as Pan02, with a clear response to known immune checkpoint inhibitors.

  • Anti-PDL-1
  • Anti-PD-1
  • Anti-CTLA-4

Applications of the syngeneic model include but are not limited to the following.

  • Responsiveness to known immunomodulatory therapies
  • Extent and composition of tumor-infiltrating lymphocytes (TILs)
  • Immunogenicity testing

Syngeneic Mouse Model Strains

We offer syngeneic mouse models with and without profiles. The following syngeneic models are available.

  • CD1
  • Swiss Nude
  • B6
  • NSG
  • Balb/c
  • CB17
  • Balb/SCID
  • CD57BL
  • NOD/SCID
  • Nu/nu

In addition to a wide range of mouse models, Alfa Cytology offers comprehensive pharmacodynamics, toxicology evaluation, and pharmacokinetics services in the syngeneic model.

Why Choose Us?

Scientific Experience

Professional team of scientists and more than ten years of experience in pancreatic cancer

Customized Service

Tailored services dedicated to ensuring customer satisfaction

Data Security

Strictly keep confidential the client's project information and experimental data

Quick Reply

Our customer service representatives are available 24 hours a day from Monday to Sunday

With syngeneic models that respond to immunotherapy, patient-derived xenotransplantation (PDX) models, humanized models, and preclinical validation platforms, Alfa Cytology is the ideal partner to advance your immuno-oncology pipeline. Based on our comprehensive expertise in pancreatic cancer and advanced technology platform, we can develop various PC syngeneic models for our customers for research and preclinical purposes. If you are interested in our services, please contact us for more details. You can contact our staff directly and receive professional, reliable, and fast feedback.

Reference

  1. Chulpanova, D.S.; et al. Mouse Tumor Models for Advanced Cancer Immunotherapy. Int. J. Mol. Sci. 2020, 21, 4118. https://doi.org/10.3390/ijms21114118
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.